Zobrazeno 1 - 10
of 10
pro vyhledávání: '"D M, Karpf"'
Autor:
Gert Bolt, Peter B. Johansen, Helle Heibroch Petersen, Henrik Rahbek-Nielsen, D. M. Karpf, Peder Lisby Nørby, Mette Loftager, Marianne Kjalke, Lars Thim, E. Bloem, G. E. Blouse
Publikováno v:
Journal of Thrombosis and Haemostasis. 17:350-360
Essentials Factor (F)VIII with an intermediate-length B-domain showed higher levels in murine gene therapy. FVIII with different B-domain lengths were analysed. FVIII variants with B-domains between 186 and 240 amino acids (aa) have extended half-lif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a71795725da862caf2148eb40463f37e
https://doi.org/10.1111/jth.14355
https://doi.org/10.1111/jth.14355
Autor:
J. Bøggild Kristensen, C. N. Gudme, Rupa S. Appa, D. M. Karpf, Gert Bolt, Carsten Behrens, Kirstine Roepstorff, Marianne Kjalke, Cristina Ionica Øie, Bård Smedsrød
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:1803-1813
UNLABELLED Essentials Von Willebrand factor (VWF) stabilizes factor VIII (FVIII) and prevents its premature clearance. Rat anatomical and hepatocellular distribution studies assessed the VWF effect on FVIII clearance. Hepatocytes and liver sinusoidal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e4ad0fc0ad70df820699509a87fc2d
https://doi.org/10.1111/jth.13406
https://doi.org/10.1111/jth.13406
Autor:
Mads Kreilgaard, Peter B. Johansen, Jesper Haaning, Frederik Rode, L. F. Larsen, Mette Loftager, K. Almholt, Maj Petersen, Marianne Kjalke, D. M. Karpf, Andreas Velsing Groth
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 16(6)
Essentials N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous (SC) FVIII dosing might reduce the treatment burden of prophylaxis. SC N8-GP has a favorable PK profile in animal models and dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52535d6af3770733e2993fb3cc33722c
https://pubmed.ncbi.nlm.nih.gov/29582559
https://pubmed.ncbi.nlm.nih.gov/29582559
Autor:
Torben Elm, Marianne Kjalke, Mikael Tranholm, D. M. Karpf, Mirella Ezban, Hermann Pelzer, K. Øvlisen
Publikováno v:
Haemophilia. 18:139-145
N8 is a new recombinant factor VIII (rFVIII) compound produced and formulated without human- or animal-derived protein. The aims of the present studies were to evaluate the pharmacokinetics and pharmacodynamics properties of N8 and to compare with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09ac6742bb8174b9d6965ba6964b54bd
https://doi.org/10.1111/j.1365-2516.2011.02608.x
https://doi.org/10.1111/j.1365-2516.2011.02608.x
Autor:
A L Kirkegaard, Peter J. Hayball, Allan M. Evans, D M Karpf, Robert W. Milne, Roger L. Nation
Publikováno v:
Journal of Pharmacy and Pharmacology. 55:1641-1646
Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit the renal tubular secretion of methotrexate. However, the relative contribution of the active S- and inactive R-enantiomers is unknown. This study examined the effect of racemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e79b17965d7d189ec6a02f5a0120f4
https://doi.org/10.1211/0022357022287
https://doi.org/10.1211/0022357022287
Autor:
Søren E. Bjørn, D. M. Karpf, Henning R. Stennicke, Mirella Ezban, Torben Elm, Heidi L. Holmberg, Mikael Tranholm
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:1070-1072
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f4ce8c3ec2983eff635d1e241e9625a
https://doi.org/10.1111/j.1538-7836.2011.04252.x
https://doi.org/10.1111/j.1538-7836.2011.04252.x
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(1)
N8 is a new recombinant factor VIII (rFVIII) compound produced and formulated without human- or animal-derived protein. The aims of the present studies were to evaluate the pharmacokinetics and pharmacodynamics properties of N8 and to compare with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a9dea00dd70cd60a9e68aef08ec55bf4
https://pubmed.ncbi.nlm.nih.gov/21771205
https://pubmed.ncbi.nlm.nih.gov/21771205
Autor:
D M, Karpf, M, Kjalke, L, Thim, H, Agersø, E P, Merricks, N, Defriess, T C, Nichols, M, Ezban
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(5)
N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and formulated without human- or animal-derived materials. The aim of the present study was to compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd10a82ae48a0ce351dc598c709546c5
https://pubmed.ncbi.nlm.nih.gov/21682818
https://pubmed.ncbi.nlm.nih.gov/21682818
Autor:
Elizabeth P. Merricks, D. M. Karpf, Marianne Kjalke, Natalie DeFriess, Timothy C. Nichols, Lars Thim, Mirella Ezban, Henrik Agersø
Publikováno v:
Haemophilia.
N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and formulated without human- or animal-derived materials. The aim of the present study was to compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c1405562b297543bee7693ea4f8516c
https://doi.org/10.1111/j.1365-2516.2011.02580.x
https://doi.org/10.1111/j.1365-2516.2011.02580.x
Publikováno v:
Journal of Pharmacy & Pharmacology; Dec2003, Vol. 55 Issue 12, p1641-1646, 6p